Macroaxis: Personalized Investing
Simple Personalized Investing

S&P 500   1,667   17.00  Index Moved Up 1.03%
GILD AMGN BIIB CELG ISP Management Action Alerts Beers 
United States  USA  |  Optimize Portfolios


Processing
Collecting data for REGN

Regeneron quote and profile

 
 Companies |  Insiders  | Dashboard  
     
266.97
  
STOCK
2.31  Macroaxis: 0.87 Up   0.87%  
Year To Date
107220
Trading Day 
262270
May 18 2013 

Diversification Suggestion

Use Regeneron to enhance returns of your portfolios. The stock experiences moderate upward volatility
Analyze Regeneron Pharmaceut Trend or Check current 30 days Regeneron correlation with market (S&P 500)
1 Month Beta -0.04  
Highest Price:  
Lowest Price:  
282.8  
206.66  
May 14 2013 
April 18 2013 
As returns on market increase, returns on owning Regeneron are expected to decrease at a much smaller rate. During bear market, Regeneron is likely to outperform the market.
Regeneron Pharmaceuticals Inc Almost negative betaRegeneron Pharmaceut Beta Legend
REGN United States Nasdaq
Regeneron Pharmaceuticals Inc
Healthcare
Biotechnology
http://www.regeneron.com
Contact Number: 914. 347. 7000
Currency: USD - US Dollar
Traded on NASDAQ
    
Current Valuation23.08 B
Shares Outstanding96.65 M
Number of Shares Shorted3.67 M
Revenue1.38 B
 United States Russel   1.11 % Macroaxis: change 1.11 Moved Up  
 
 United States SP 500   1.03 % Macroaxis: change 1.03 Moved Up  
 
 United States Nasdaq   0.97 % Macroaxis: 0.97 Moved Up  
 
 United States NYSE   0.92 % Macroaxis: 0.92 Moved Up  
 
 thisGreen REGN REGN agains markets  0.87 % Macroaxis: 0.87 Moved Up  
 
Compare to Competition Get Alpha   Get Advice

Regeneron Leadership

Leonard Schleifer President CEO, Director, Ph.D
Dr MD Co-Founder, Director, Chairman of Corporate Governance and Compliance Committee and Member of Technology Committee
P Vagelos Chairman of the Board, Ph.D
Michael Aberman Vice President - Strategy and Investor Relations, MBA

Regeneron Price and Market Media

The median price of Regeneron for the period between Thu, Apr 18, 2013 and Sat, May 18, 2013 is 261.95 with a coefficient of variation of 11.33. The daily time series for the period is distributed with a sample standard deviation of 27.64, arithmetic mean of 243.9, and mean deviation of 25.56. The Stock received substential amount of media coverage during this period.
Regeneron         Market
Price Growth (%)
 
1
REGENERON PHARMACEUTICALS INC Regeneron Announces Upcoming ....04/19/2013Macroaxis: News
2
Regeneron Pharmaceuticals to Replace MetroPCS in SandP 500 I...04/25/2013Macroaxis: Bloomberg News
3
Regeneron Pharmaceuticals Inc Sanofi SA Arena ...05/01/2013Macroaxis: News
4
Regeneron Pharmaceuticals Earnings Preview Can This Streak C...05/03/2013Macroaxis: News
5
NASDAQ Decliners Watch List Regeneron Pharmaceuticals Inc. N...05/07/2013Macroaxis: News
6
Regeneron Pharmaceuticals Inc Eylea Fundamentals Improving A...05/10/2013Macroaxis: News
7
First Solar Inc. Regeneron Pharmaceuticals Inc Advanced ...05/13/2013Macroaxis: News
8
NASDAQ Active Stock Watch List Idenix Pharmaceuticals Inc. N...05/16/2013Macroaxis: News

Regeneron Summary

Regeneron Pharmaceuticals Inc [REGN] is traded on NASDAQ in USA. It is located in Regeneron Pharmaceuticals, Inc.Tarrytown, NY and employs 1,950 people. The company currently falls under 'Large-Cap' category with current market capitalization of 22.93 B. Regeneron Pharmaceuticals Inc conducts business under Healthcare sector and is part of Biotechnology industry. This company has 96.65 M outstanding shares of which 3.67 M shares are at this time shorted by private and institutional investors with about 6.0 trading days to cover.
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. more
Past Market
Over 30
Days
20
Out Of
100
 
Chance of
Less
Than
%
 
Follow Regeneron with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add Regeneron to your reader
 

Regeneron Research Report

Regeneron vs. Gilead

Correlation analysis and fundamentals comparison between Regeneron Pharmaceut and Gilead Sciences

Regeneron Executives

Murray Goldberg CFO, Sr. VP of Fin. and Admin. and Assistant Secretary, MBA

Regeneron Directors

Joseph Goldstein Independent Director
Christine Poon Independent Director
Charles Baker Independent Director
Mr MD Chief Scientific Officer, Executive VP, Director, Ex Officio Member of Technology Committee and President of Regeneron Research Laboratories
Michael Brown Independent Director, Ph.D

Regeneron Fundamentals

EBITDA vs Current Asset
Total Debt vs Beta
EBITDA vs Market Capitalization
Profit Margin vs Beta

Regeneron vs Competition

Regeneron vs. Gilead Sciences Inc
Regeneron vs. Amgen Inc
Regeneron vs. Biogen Idec Inc
Regeneron vs. Celgene Corporation
Regeneron vs. Alexion Pharmaceuticals Inc
Regeneron vs. Vertex Pharmaceuticals Incorporated
Regeneron vs. Illumina Inc
Regeneron vs. BioMarin Pharmaceutical Inc
Regeneron vs. Onyx Pharmaceuticals Inc

Regeneron May 18 2013 Opportunity Range

Downside Deviation1.67
Information Ratio0.2681
Maximum Drawdown13.74
Value At Risk(3.07)
Potential Upside7.05

 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium